A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

NCT00306189 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: 100 mg AMG 162
DRUG: 60 mg AMG 162
DRUG: 14 mg AMG 162
DRUG: Placebo

Sponsor

Amgen